Facebook
Twitter
LinkedIn
ForwardSession 1 (9/11/2025): BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics
Session 1 (9/11/2025): BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics
Topic: Introduction to BCMA-directed bispecific antibodies, approved and investigational agents
Session: 7-8 pm ET / 6-7 pm CT / 5-6 pm MT / 4-5 pm PT
How to Earn Credit
In order to successfully complete this activity, you are required to attend the live meeting and complete and complete the post-test and evaluation. Once completed your credit will be recorded and saved to your account.
How to Request a Certificate
By attending the course and completing the evaluation and posttest, physicians are entitled to receive 1 AMA PRA Category 1 Credits™ and 1 MOC point for the ABIM Maintenance of Certification (MOC), nurses are entitled to receive 1 CNE contact hours, all of which are eligible for pharmacology hours, pharmacists will receive 1 CPE credits, and physician associates will receive 1 AAPA Category 1 CME credits.
To receive a certificate for your participation in this activity, you will need to create an account on the CME Office's website and complete the evaluation survey. Then your certificate will be available for immediate download.
Target Audience
Oncologists, hematologists, PAs, NPs, nurses, nurse navigators, pharmacists and other healthcare professionals (HCPs) responsible for the care and treatment of people living with RRMM.
Learning Objectives
At the conclusion of this session, participants will be able to:
- TBD
Didactic Presenter:
Raphael E. Szalat, MD, PhD
Assistant Professor of Medicine
Director, Multiple Myeloma Program
Director, Stem Cell Transplant Program
Section of Hematology and Medical Oncology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, MA
Raphael E. Szalat, MD, PhD received his medical training at the University of Pierre and Marie Curie in Paris, France. After internal medicine residency, Szalat specialized in immunology and plasma cell disorders, including multiple myeloma and monoclonal gammopathies of clinical significance, and became a clinical assistant professor in the Department of Immuno-Hematology in Saint-Louis Hospital, Paris. He next completed a PhD and postdoc in hematology, studying genomics in multiple myeloma at the Dana-Farber Cancer Institute, Harvard Medical School, in collaboration with La Sorbonne University, Paris, and a clinical fellowship in hematology and oncology at the Boston University Medical Center.
Dr. Szalat currently serves as director of the Multiple Myeloma Program and the Stem Cell Transplant Program at the Boston University Medical Center. His main interests are developing myeloma clinical trials and performing basic and translational research on multiple myeloma and other plasma cell disorders, including AL amyloidosis and other monoclonal gammopathies of clinical significance.
Dr. Raphael Szalat, program Co-Chair, is a consultant for Johnson & Johnson.
Grantor Acknowledgement
This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Accreditation Statement
This activity is developed as a joint collaboration among Boston University Chobanian & Avedisian School of Medicine, Med-IQ, the AAPA, the Association of PAs in Oncology (APAO), and HealthTree Foundation.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
Nurse Accreditation
Nursing Contact Hours: 1.0, of which 1.0 is eligible for pharmacology credit.
Pharmacist Accreditation
This activity is approved for 1.0 CPE credit.
Physician Associate Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category I CME
- 1.00 ABMS MOC II
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 ANCC Pharmacology